Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Multiple Myeloma 36Neoplasms, Plasma Cell 12Prostatic Neoplasms 4Neoplasms 3Lymphoma, Mantle-Cell 3Immunoglobulin Light-chain Amyloidosis 3Central Nervous System Neoplasms 3Waldenstrom Macroglobulinemia 2Sarcoma 2Recurrence 2Rectal Neoplasms 2Neuroblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Amyloidosis 2Adenocarcinoma of Lung 2Renal Insufficiency, Chronic 1Renal Insufficiency 1Polyneuropathies 1Paraproteinemias 1Neurotoxicity Syndromes 1Motor Activity 1

Interventions

Rituximab 49fludarabine phosphate 32Cyclophosphamide 30Whole-Body Irradiation 26Peripheral Blood Stem Cell Transplantation 25Mycophenolic Acid 24Tacrolimus 19Cyclosporine 16Dexamethasone 13Busulfan 13ibrutinib 12Sirolimus 12Bortezomib 11Antilymphocyte Serum 11Melphalan 10Etoposide 10Calcium Dobesilate 10Methotrexate 8Lenalidomide 8Cyclosporins 8idelalisib 7Everolimus 6Indium 5Filgrastim 5thymoglobulin 4ibritumomab tiuxetan 4carfilzomib 4Vincristine 4Prednisone 4In Situ Hybridization, Fluorescence 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Waldenstrom Macroglobulinemia × Thalidomide × Clear all
NCT01779167 2018-07-11

THRiL for WM

Weill Medical College of Cornell University

Phase 2 Terminated
4 enrolled 5 charts
Lymphoid

Waldenstrom Macroglobulinemia

NCT00142116 2014-06-02

Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

Dana-Farber Cancer Institute

Phase 2 Completed
25 enrolled 8 charts
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡